MedPath

VORICONAZOLE

These highlights do not include all the information needed to use VORICONAZOLE FOR INJECTION safely and effectively. See full prescribing information for VORICONAZOLE FOR INJECTION. VORICONAZOLE for injection, for intravenous use Initial U.S. Approval: 2002

Approved
Approval ID

63473087-5cc1-b2e8-b552-6d5f733e1227

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 5, 2023

Manufacturers
FDA

Alvogen Inc.

DUNS: 008057330

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

VORICONAZOLE

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code47781-466
Application NumberANDA206398
Product Classification
M
Marketing Category
C73584
G
Generic Name
VORICONAZOLE
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateMay 5, 2021
FDA Product Classification

INGREDIENTS (2)

BETADEX SULFOBUTYL ETHER SODIUMInactive
Code: 2PP9364507
Classification: IACT
VORICONAZOLEActive
Quantity: 10 mg in 1 mL
Code: JFU09I87TR
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

VORICONAZOLE - FDA Drug Approval Details